MMP protein and activity levels in synovial fluid from patients with joint injury, inflammatory arthritis, and osteoarthritis

Annals of the Rheumatic Diseases

Volumn 64, Issue 5, 2005, Pages 694-698

  Tchetverikov, I ^a   Lohmander, L S ^c   Verzijl, N ^a   Huizinga, T W J ^b   TeKoppele, J M ^a   Hanemaaijer, R ^a   DeGroot, J ^a  

^a TNO   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 MACROGLOBULIN; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE; PROINTERSTITIAL COLLAGENASE; PROSTROMELYSIN; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 3; UNCLASSIFIED DRUG;

ARTHRITIS; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; IMMUNOASSAY; JOINT INJURY; KNEE; MAJOR CLINICAL STUDY; OSTEOARTHRITIS; PRIORITY JOURNAL; PROTEIN DETERMINATION; PSEUDOGOUT; QUANTITATIVE ANALYSIS; SYNOVIAL FLUID LEVEL;

ACUTE DISEASE; ADULT; ALPHA-MACROGLOBULINS; ARTHRITIS; CHONDROCALCINOSIS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; KNEE INJURIES; MALE; MATRIX METALLOPROTEINASES; MIDDLE AGED; OSTEOARTHRITIS, KNEE; SYNOVIAL FLUID; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 17644414532     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2004.022434     Document Type: Article

References (53)

1. Mankin HJ. Clinical features of osteoarthritis. In: Kelley WN, Harris ED, Ruddy S, Sledge CB, eds. Textbook of rheumatology. Philadelphia: W B Saunders, 1993:1374-84.
2. Fairbank TJ. Knee joint changes after meniscectomy. J Bone Joint Surg Br 1948;30B:664-70.
3. Appel H. Late results after meniscectomy in the knee joint. A clinical and roentgenologic follow-up investigation. Acta Orthop Scand Suppl 1970;133:1-111.
4. Johnson RJ, Kettelkamp DB, Clark W, Leaverton P. Factors effecting late results after meniscectomy. J Bone Joint Surg Am 1974;56:719-29.
5. Sherman MF, Warren RF, Marshall JL, Savatsky GJ. A clinical and radiographical analysis of 127 anterior cruciate insufficient knees. Clin Orthop 1988;227:229-37.
6. Cicuttini FM, Forbes A, Yuanyuan W, Rush G, Stuckey SL. Rate of knee cartilage loss after partial meniscectomy. J Rheumatol 2002;29:1954-6.
7. Englund M, Roos EM, Roos HP, Lohmander LS. Patient-relevant outcomes fourteen years after meniscectomy: influence of type of meniscal tear and size of resection. Rheumatology (Oxford) 2001;40:631-9.
8. Englund M, Roos EM, Lohmander LS. Impact of type of meniscal tear on radiographic and symptomatic knee osteoarthritis: a sixteen-year followup of meniscectomy with matched controls. Arthritis Rheum 2003;48:2178-87.
9. Caterson B, Hughes CE, Johnstone B, Mort JS. Immunological markers of cartilage proteoglycan metabolism in animal and human osteoarthritis. In: Kuettner KE, Schleyerbach R, Peyron JG, Hascall VC, eds. Articular cartilage and osteoarthritis. New York: Raven Press, 1992:415-27.
10. Dahlberg L, Roos H, Saxne T, Heinegard D, Lark MW, Hoerrner LA, et al. Cartilage metabolism in the injured and uninjured knee of the same patient. Ann Rheum Dis 1994;53:823-7.
11. Roos H, Dahlberg L, Hoerrner LA, Lark MW, Thonar EJ, Shinmei M, et al. Markers of cartilage matrix metabolism in human joint fluid and serum: the effect of exercise. Osteoarthritis Cartilage 1995;3:7-14.
12. Lohmander LS, Saxne T, Heinegard DK. Release of cartilage oligomeric matrix protein (COMP) into joint fluid after knee injury and in osteoarthritis. Ann Rheum Dis 1994;53:8-13.
13. Lohmander LS, Ionescu M, Jugessur H, Poole AR. Changes in joint cartilage aggrecan after knee injury and in osteoarthritis. Arthritis Rheum 1999;42:534-44.
14. Lohmander LS, Hoerrner IA, Dahlberg L, Roos H, Biornsson S, Lark MW. Stromelysin, tissue inhibitor of metalloproteinases and proteoglycan fragments in human knee joint fluid after injury. J Rheumatol 1993;20:1302-8.
15. Lohmander LS, Roos H, Dahlberg L, Hoerrner LA, Lark MW. Temporal patterns of stromelysin-1, tissue inhibitor, and proteoglycan fragments in human knee joint fluid after injury to the cruciate ligament or meniscus. J Orthop Res 1994;12:21-8.
16. Murphy G, Knauper V, Atkinson S, Butler G, English W, Hutton M et al. Matrix metalloproteinases in arthritic disease. Arthritis Res 2002;4(suppl 3):S39-49.
17. Knauper V, Bailey L, Worley JR, Soloway P, Patterson ML, Murphy G. Cellular activation of proMMP-13 by MT1-MMP depends on the C-terminal domain of MMP-13. FEBS Lett 2002;532:127-30.
18. Nagase H, Okada Y. Proteinases and matrix degradation. In: Kelley WN, Harris ED, Ruddy S, Sledge CB, eds. Textbook of rheumatology. Philadelphia: WB Saunders, 1998:323-41.
19. Nagase H, Woessner JFJ. Matrix metalloproteinases. J Biol Chem 1999;274:21491-94.
20. Konttinen YT, Ainola M, Valleala H, Ma J, Ida H, Mandelin J, et al. Analysis of 16 different matrix metalloproteinases (MMP-1 to MMP-20) in the synovial membrane: different profiles in trauma and rheumatoid arthritis. Ann Rheum Dis 1999;58:691-7.
21. Lohmander LS, Hoerrner LA, Lark MW. Metalloproteinases, tissue inhibitor, and proteoglycan fragments in knee synovial fluid in human osteoarthritis. Arthritis Rheum 1993;36:181-9.
22. Moore AR, Appelboam A, Kawabata K, Da Silva JA, D'Cruz D, Gowland G, et al. Destruction of articular cartilage by alpha 2 macroglobulin elastase complexes: role in rheumatoid arthritis. Ann Rheum Dis 1999;58:109-13.
23. Walakovits LA, Moore VL, Bhardwaj N, Gallick GS, Lark MW. Detection of stromelysin and collagenase in synovial fluid from patients with rheumatoid arthritis and posttraumatic knee injury. Arthritis Rheum 1992;35:35-42.
24. Gruber BL, Sarbi D, French DL, Marchese MJ, Nuovo GJ, Kew RR, et al. Markedly elevated serum MMP-9 (gelatinase B) levels in rheumatoid arthritis: a potentially useful laboratory marker. Clin Immunol Immunopathol 1996;78:161-71.
25. Ishiguro N, Ito T, Obata K, Fujimoto N, Iwata H. Determination of stromelysin-1, 72 and 92 kDa type IV collagenase, tissue inhibitor of metalloproteinase-1 (TIMP-1), and TIMP-2 in synovial fluid and serum from patients with rheumatoid arthritis. J Rheumatol 1996;23:1599-604.
26. Itoh T, Uzuki M, Shimamura T, Sawai T. [Dynamics of matrix metalloproteinase (MMP)-13 in the patients with rheumatoid arthritis]. Ryumachi 2002;42:60-9.
27. Ishiguro N, Ito T, Miyazaki K, Iwata H. Matrix metalloproteinases, tissue inhibitors of metalloproteinases, and glycosaminoglycans in synovial fluid from patients with rheumatoid arthritis. J Rheumatol 1999;26:34-40.
28. Yoshihara Y, Nakamura H, Obata K, Yamada H, Hayakawa T, Fujikawa K, et al. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids from patients with rheumatoid arthritis or osteoarthritis. Ann Rheum Dis 2000;59:455-61.
29. Maeda S, Sawai T, Uzuki M, Takahashi Y, Omoto H, Seki M, et al. Determination of interstitial collagenase (MMP-1) in patients with rheumatoid arthritis. Ann Rheum Dis 1995;54:970-5.
30. Martel-Pelletier J, McCollum R, Fujimoto N, Obata K, Cloutier JM, Pelletier JP. Excess of metalloproteases over tissue inhibitor of metalloprotease may contribute to cartilage degradation in osteoarthritis and rheumatoid arthritis. Lab Invest 1994;70:807-15.
31. Drijfhout JW, Nagel JBB, TeKoppele JM, Bloemhoff W. Solid phase synthesis of peptides containing the fluorescence energy transfer Dabcyl-EDANS coupe. In: Kaumaya PTP, Hoages RS, eds. Peptides, chemistry, structure and biology. Mayflower Scientific Ltd, 1990:129-31.
32. Beekman B, Drijfhout JW, Bloemhoff W, Ronday HK, Tak PP, te Koppele JM. Convenient fluorometric assay for matrix metalloproteinase activity and its application in biological media. FEBS Lett 1996;390:221-5.
33. Grinnell F, Zhu M, Parks WC. Collagenase-1 complexes with alpha2-macroglobulin in the acute and chronic wound environments. J Invest Dermotol 1998;110:771-6.
34. Beekman B, van El B, Drijfhout JW, Ronday HK, TeKoppele JM. Highly increased levels of active stromelysin in rheumatoid synovial fluid determined by a selective fluorogenic assay. FEBS Lett 1997;418:305-9.
35. Woessner JFJ. Matrix metalloproteinase inhibition. From the Jurassic to the third millennium. Ann NY Acad Sci 1999;878:388-403.
36. Cawston TE, Mercer E. Preferential binding of collagenase to alpha 2-macroglobulin in the presence of the tissue inhibitor of metalloproteinases. FEBS Lett 1986;209:9-12.
37. Tchetverikov I, Verzijl N, Huizinga TWJ, TeKoppele JM, Hanemaaijer R, DeGroot J. Active MMPs captured by alpha(2)macroglobulin as a marker of disease activity in rheumatoid arthritis. Clin Exp Rheumatol 2003;21:711-18.
38. Cunnane G, Fitzgerald O, Beeton C, Cawston TE, Bresnihan B. Early joint erosions and serum levels of matrix metalloproteinase 1, matrix metalloproteinase 3, and tissue inhibitor of metalloproteinases 1 in rheumatoid arthritis. Arthritis Rheum 2001;44:2263-74.
39. Cooksley S, Hipkiss JB, Tickle SP, Holmes-levers E, Docherty AJ, Murphy G, et al. Immunoassays for the detection of human collagenase, stromelysin, tissue inhibitor of metalloproteinases (TIMP) and enzyme-inhibitor complexes. Matrix 1990;10:285-91.
40. DeGroot J, Verzijl N, Budde M, Bijlsma JW, Lafeber FP, TeKoppele JM. Accumulation of advanced glycation end products decreases collagen turnover by bovine chondrocytes. Exp Cell Res 2001;266:303-10.
41. Riley GP, Curry V, DeGroot J, van El B, Verzijl N, Hazleman BL, et al. Matrix metalloproteinase activities and their relationship with collagen remodelling in tendon pathology. Matrix Biol 2002;21:185-95.
42. Brandt KD, Mankin HJ. Pathogenesis of osteoarthritis. In: Kelley WN, Harris ED, Ruddy S, Sledge CB, eds. Textbook of rheumatology. Philadelphia: WB Saunders, 1993:1355-73.
43. Lohmander LS, Neame PJ, Sandy JD. The structure of aggrecan fragments in human synovial fluid. Evidence that aggrecanase mediates cartilage degradation in inflammatory joint disease, joint injury, and osteoarthritis. Arthritis Rheum 1993;36:1214-22.
44. Lohmander LS, Saxne T, Heinegard D. Increased concentrations of bone sialoprotein in joint fluid after knee injury. Ann Rheum Dis 1996;55:622-6.
45. Abbink JJ, Kamp AM, Nieuwenhuys EJ, Nuijens JH, Swaak AJ, Hack CE. Predominant role of neutrophils in the inactivation of alpha 2-macroglobulin in arthritic joints. Arthritis Rheum 1991;34:1139-50.
46. Cawston TE, McLaughlin P, Hazleman BL. Paired serum and synovial fluid values of alpha 2-macroglobulin and TIMP in rheumatoid arthritis. Br J Rheumatol 1987;26:354-8.
47. Tchetverikov I, Ronday HK, van El B, Kiers GH, Verzijl N, TeKoppele JM, et al. MMP profile in paired serum and synovial fluid samples of patients with rheumatoid arthritis. Ann Rheum Dis 2004;63:881-3.
48. Feldman SR, Rosenberg MR, Ney KA, Michalopoulos G, Pizzo SV. Binding of alpha 2-macroglobulin to hepatocytes: mechanism of in vivo clearance. Biochem Biophys Res Commun 1985;128:795-802.
49. van Leuven F. Human alpha 2 macroglobulin. Mol Cell Biochem 1984;58:121-8.
50. Tchetverikov I, Lard LR, DeGroot J, Verzijl N, TeKoppele JM, Breedveld FC, et al. Matrix metalloproteinases-3,-8,-9 as markers of disease activity and joint damage progression in early rheumatoid arthritis. Ann Rheum Dis 2003;62:1094-9.
51. Brew K, Dinakarpandian D, Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta 2000;1477:267-83.
52. Posthumus MD, Limburg PC, Westra J, van Leeuwen MA, van Rijswijk MH. Serum matrix metalloproteinase 3 in early rheumatoid arthritis is correlated with disease activity and radiological progression. J Rheumatol 2000;27:2701-8.
53. Ribbens C, Porras M, Franchimont N, Kaiser MJ, Jaspar JM, Damas P, et al. Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment. Ann Rheum Dis 2002;61:161-6.